NIH grant could be worth up to $10m to SAGE Therapeutics and its Fragile X Syndrome drug SAGE Therapeutics, a Cambridge company seeking to develop medicines to treat central nervous disorders, said Wednesday that it has been awarded a National Institutes of Health grant that will support a drug candidate that could be used to treat anxiety and social deficits in patients with Fragile X Syndrome, or FXS. FXS is a monogenic form of autism and an orphan condition causing significant ...
July 31, 2013 - Boston.com